Forian Inc. has entered into a definitive merger agreement to be acquired by a consortium of investors led by Chairman and Chief Executive Officer Max Wygod, together with certain other senior executives and existing stockholders. The all-cash transaction values the company's equity at approximately $68 million and will return Forian to private ownership. Under the agreement, Forian stockholders will receive $2.17 per share in cash, representing a premium of approximately 22.6% to the company's unaffected closing price as of August 22, 2025. The transaction was unanimously approved by the Forian Board of Directors, acting upon the unanimous recommendation of a Special Committee of disinterested and independent directors formed in response to the consortium's initial proposal.
The transaction is expected to close in the second quarter of 2026, subject to the satisfaction of the minimum tender condition and other closing conditions. Following completion, Forian will no longer be listed on the Nasdaq Stock Market or any public exchange. The company will continue to be led by Max Wygod and the current leadership team, maintaining its headquarters in Newtown, Pennsylvania and operating under the Forian name. Forian provides data management capabilities and proprietary information and analytics solutions for customers in life sciences, healthcare, and financial services. The company has industry leading expertise in acquiring, integrating, normalizing and commercializing large-scale healthcare data assets. More information about the company is available at https://www.forian.com.
Concurrent with entering into the merger agreement, consortium members have committed to provide the funding necessary to pay the cash consideration, and the transaction is not subject to a financing condition. The Forian Board of Directors unanimously recommends that all stockholders tender their shares into the offer. Important documents related to the transaction will be filed with the SEC and available at https://www.sec.gov. Investors may also obtain these documents under the "Investors" section of the company's website. The solicitation and offer to purchase shares will only be made pursuant to formal tender offer materials that will be filed with regulatory authorities.
This acquisition matters because it represents a significant shift in ownership structure for a company specializing in critical healthcare and life sciences data analytics. The move to private ownership, led by its own CEO and executives, suggests a strategic decision to operate away from public market pressures, potentially allowing for more focused long-term investments in its data management platforms. The premium offered to shareholders reflects confidence in the company's underlying value and future prospects under continued leadership. For the industries it serves—life sciences, healthcare, and financial services—this transition could imply stability in Forian's operations and commitment to its proprietary solutions, as the leadership and headquarters remain unchanged. The deal's structure, with committed funding and no financing condition, underscores the consortium's readiness and reduces transaction risk, aiming for a smooth transition that benefits stockholders through immediate cash value while positioning the company for its next phase of growth outside the public eye.
